




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Can hyperbaric oxygen safely serve as an anti-inflammatory treatment for COVID-19?



Anders Kjellberg^{a,b,*}, Antonio De Maio^{c,d}, Peter Lindholm^{a,e}

^a Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden

^b Perioperative Medicine and Intensive Care Medicine, Karolinska University Hospital, Stockholm, Sweden

^c Division of Trauma, Critical Care, Burns and Acute Care Surgery, Department of Surgery, University of California San Diego, La Jolla, CA 92093, USA

^d Department of Neurosciences, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA

^e Department of Emergency Medicine, University of California San Diego, La Jolla, CA 92093, USA

ABSTRACT

Introduction: SARS-CoV-2 affects part of the innate immune response and activates an inflammatory cascade stimulating the release of cytokines and chemokines, particularly within the lung. Indeed, the inflammatory response during COVID-19 is likely the cause for the development of acute respiratory distress syndrome (ARDS). Patients with mild symptoms also show significant changes on pulmonary CT-scan suggestive of severe inflammatory involvement.

Hypothesis: The overall hypothesis is that HBO₂ is safe and reduces the inflammatory response in COVID-19 pneumonitis by attenuation of the innate immune system, increase hypoxia tolerance and thereby prevent organ failure and reduce mortality.

Evaluation of the hypothesis: HBO₂ is used in clinical practice to treat inflammatory conditions but has not been scientifically evaluated for COVID-19. Experimental and empirical data suggests that HBO₂ may reduce inflammatory response in COVID-19. However, there are concerns regarding pulmonary safety in patients with pre-existing viral pneumonitis.

Empirical data: Anecdotes from “compassionate use” and two published case reports show promising results.

Consequences of the hypothesis and discussion: Small prospective clinical trials are on the way and we are conducting a randomized clinical trial.

Introduction

SARS-CoV-2 affects part of the innate immune response and activates an inflammatory cascade stimulating the release of cytokines and chemokines, particularly within the lung [1,2]. The export of these factors attracts neutrophils and monocytes to the site of infection, infiltrating the organ. Unfortunately, neutrophils are particularly inefficient in clearing viral infections, and their presence may be more detrimental than beneficial due to the release of a battery of caustic agents directed at killing the pathogen, but they could also damage the surrounding tissue [3]. The destruction of host cells may release sub-cellular elements that could trigger secondary inflammatory reactions. Thus, SARS-CoV-2 infection activates a robust inflammatory response that if it is not controlled, could result in a “cytokine storm” with detrimental systemic consequences [4]. Indeed, the inflammatory response during COVID-19 is likely the cause for the development of acute respiratory distress syndrome (ARDS) in patients, which is a condition of very low arterial oxygen concentration or hypoxia and bilateral pulmonary opacities [5]. A post-mortem biopsy of pulmonary

tissue from a 72-year-old man that died 3 weeks after the onset of symptoms was described as “diffuse alveolar damage, with reactive type II pneumocyte hyperplasia, intra-alveolar fibrinous exudates were present and loose interstitial fibrosis and chronic inflammatory infiltrates” [6]. Even patients that have mild symptoms and survived COVID-19 displayed significant changes on pulmonary CT-scan, with diffuse ground-glass opacities, crazy-paving patterns, and consolidation, suggesting a severe inflammatory involvement [7].

So far, specific treatments have been difficult to advance among more than 160 clinical trials registered since March 2020 [8]. Recently, a double-blind clinical trial using the drug Remdesivir, which was originally developed for the treatment of Ebola virus, showed an improvement in the resolution of severely ill COVID-19 patients, opening a ray of hope [9]. However, a cure for the disease is still yet to come. Several groups are also rapidly working on the development of a possible vaccine, but this endeavour may be months or years away from reality.

Hyperbaric Oxygen (HBO₂) consists of exposure to 100% oxygen under increased atmospheric pressure. This procedure allows the

* Corresponding author.

E-mail address: anders.kjellberg@ki.se (A. Kjellberg).

¹ ORCID ID: 0000-0002-4819-1024.

delivery of oxygen at high partial pressure reaching tissues rapidly at elevated concentrations. HBO₂ has been used for almost a century, initially for decompression sickness (DCS), but it was soon noted that it had several anti-inflammatory effects [10,11]. HBO₂ is shown to be effective in treatment of radiation injury [12–14] and wound healing [15]. In all cases, HBO₂ has been used with great safety, and with very few adverse effects.

The hypothesis

The overall hypothesis is that HBO₂ is safe and reduces the inflammatory response in COVID-19 pneumonitis by attenuation of the innate immune system, increase hypoxia tolerance and thereby prevent organ failure and reduce mortality.

We propose that HBO₂ could be an early intervention for COVID-19 patients, utilized at the first signs of decline in oxygen blood saturation levels as well as for critically ill patients. A few treatments with HBO₂ has the potential to reduce inflammation, restore normal defence mechanisms and thereby reduce the detrimental effects of oxygen requirement in COVID-19 pneumonitis.

Evaluation of the hypothesis

Recent evidence from animal studies suggest that HBO₂ ameliorate inflammation in Decompression Sickness (DCS) induced Acute lung injury (ALI) through polarization of macrophages from inflammatory macrophage subtype (M1) to resolving or anti-inflammatory sub type (M2) [16,17]. Hyperbaric oxygen has been shown to polarize macrophages from M1 to M2 associated with IL-10 and thereby reduce inflammation [18,19] and 30 min HBO₂ ex vivo inhibit monocyte IL-1 β and TNF- α [20]. Interestingly, the switch from M1 to M2 was described in a human study of ALI/ARDS [21].

HBO₂ allows the delivery of oxygen at high partial pressure reaching tissues rapidly at elevated concentrations, which could reverse the hypoxic condition and preserve cellular metabolism [22]. Indeed, HBO₂ has been shown to preserve mitochondrial activity [23]. Moreover, HBO₂ improved kidney function after infection [24], protected organs from ischemia/reperfusion injury [25,26], reduced UV skin damage [27], and avoided kidney damage in diabetic patients [28]. Studies using an experimental animal model of sepsis that is characterized by an overwhelming inflammatory response showed a significant improvement in mortality after a single HBO₂ treatment (2.4 Atmospheres absolute (ATA), 60 min) very early after the initial insult. The improved outcome was correlated to a reduction in inflammation [29]. This observation echoes prior investigations using multiple HBO₂ treatments to improve the outcome of rodent sepsis [18]. Additionally, HBO₂ was reported to reduce bacterial infections [24,30,31] and LPS toxicity [32,33]. HBO₂ has been noticed to display several anti-inflammatory effects [10,11,29], perhaps due to modulation of oxidative stress [34], or a direct effect on the innate immune system [35]. HBO₂ significantly reduces inflammatory cytokines through several transcriptional factors, including Hypoxia Inducible Factor 1 (HIF-1) [36,37] and nuclear factor kappa-light-chain-enhancer of activated B cells

(NFkB) [18–20,38]. Other studies have shown that HBO₂ activates additional transcriptional factors, including Nuclear factor erythroid 2-related factor 2 (Nrf-2) and Heat shock factor 1 (HSF1), that are involved in the expression of several defense proteins [39]. HBO₂ has been evaluated in clinical trials as safe and may be effective for a number of acute inflammatory conditions such as pancreatitis [40], ulcerative colitis flares [41]. There is a wide range of pressures and times used for HBO₂ treatments, with preferences for the use of 1.6 to 2.5 ATA. Anti-inflammatory effects have been observed in conditions of 2 ATA for 60 min in the lung of healthy individuals. Thus, we hypothesize that the “dose” can be estimated as “area under the curve”. If the “area under the curve” is representing the dose, 2 ATA for 60 min

would be equivalent to 2.4 ATA for 50 min. The chosen protocol for the study aimed to enable inclusion of centres with practices (and hardware) for a range of pressures.

Oxygen is known to have several toxic effects when used for a prolonged time. Toxicity is dose dependent and measured in Units of pulmonary Toxic Dose (UPTD) also called Oxygen Tolerance Unit (OTU); tables for maximal dose is regulated for divers. One UPTD is equivalent of breathing 100% oxygen for 1 min at 1 Bar. Surprisingly UPTD is not recorded in medical practice despite oxygen for medical use is a regulated drug. It is well accepted that oxygen induce toxic changes in the lungs and airways but chronic oxygen toxicity in other organs including immunological effects are less explored [42]. Reversible and non-reversible oxygen toxicity in the eyes are well known side effects of HBO₂ that normally occur after 20–40 HBO₂ treatments [43]. It has been suggested that FiO₂ below 0.5 (50% O₂) is safe but it is known that many factors including viral infections, mechanical ventilation and other drugs can synergistically add to oxygen toxicity [42]. Acute severe toxicity is normally only seen in hyperbaric settings > 200 kPa and include CNS toxicity presenting as blurred vision and in worst case self-limiting seizures [44], occurring in < 1/10.000 treatments. Paradoxically intermittent HBO₂ has also been shown to protect lungs against oxygen toxicity by upregulation of anti-oxidative factors [45,46]. Even though concerns of pulmonary toxicity are theoretical for the proposed treatment duration [47], the extent of COVID-19 pathology is unknown and potential toxic effect of oxygen should be monitored in a randomized clinical trial.

Empirical data

The potential for the use of HBO₂ in the case of COVID-19 was demonstrated by two case reports from Wuhan, China, which showed an improvement in the condition of severely ill patients by increasing blood oxygen saturation levels and reducing lung inflammation [48]. In a recently published case series Louisiana, USA, 5 patients with “impeding intubation” was treated with hyperbaric oxygen, patients symptoms was immediately relieved and they all recovered after 1–6 treatments without intubation and mechanical ventilation [49]. In addition, HBO₂ has been reported to be safe during the use of mechanical ventilation [50].

Consequences of the hypothesis and discussion

Currently, half a dozen new clinical trials are underway in several countries, including case-controlled trials that may generate a rapid information that could be of utility in dealing with the current pandemic. HBO₂ is used on “compassionate grounds” just as other anti-inflammatory drugs such as Chloroquine, cortisone and L-6 inhibitors but randomized trials are absent and/or have been discouraging. Well designed and sufficiently powered randomized trials are needed to confirm safety and efficacy of HBO₂ for both current and future viral respiratory diseases. Hence, we have designed and planned a clinical trial in accordance with ICH-GCP and “the Helsinki Declaration”: “Safety and Efficacy of Hyperbaric Oxygen for Improvement of Acute Respiratory Distress Syndrome in Adult Patients With COVID-19; a Randomized, Controlled, Open Label, Multicentre Clinical Trial” (NCT04327505). We have ethical- and competent authority approval, initiated our first center and have included our first few subjects.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement and funding

This article has no funding. The randomized controlled trial has been planned and initiated with funding from the Swedish Research Council, made available by redirecting funds from Kenny Rodriguez-Wallberg at the department of Pathology-Oncology, Karolinska Institutet.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.mehy.2020.110224>.

References

- Perلمان S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. *Nat Rev Microbiol* 2009;7:439–50.
- Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Semin Immunopathol* 2017;39:529–39.
- Drescher B, Bai F. Neutrophil in viral infections, friend or foe? *Virus Res* 2013;171:1–7.
- Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. *Mil Med Res* 2020;7:11.
- Wilson JG, Calfee CS. ARDS subphenotypes: understanding a heterogeneous syndrome. *Critical care (London, England)* 2020;24:102.
- Zhang H, Zhou P, Wei Y, Yue H, Wang Y, Hu M, et al. Histopathologic Changes and SARS-CoV-2 Immunostaining in the Lung of a Patient With COVID-19. *Ann Intern Med* 2020.
- Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Novel coronavirus (COVID-19) pneumonia. *Radiology* 2019;2020:200370.
- Arabi YM, Murthy S, Webb S. COVID-19: a novel coronavirus and a novel challenge for critical care. *Intensive Care Med* 2020.
- Ledford H. Hopes rise for coronavirus drug remdesivir. *Nature* 2020.
- Gill AL, Bell CN. Hyperbaric oxygen: its uses, mechanisms of action and outcomes. *QJM* 2004;97:385–95.
- Thom SR. Hyperbaric oxygen: its mechanisms and efficacy. *Plast Reconstr Surg* 2011;127(Suppl 1):131S–41S.
- Bennett MH, Feldmeier J, Hampson NB, Smee R, Milross C. Hyperbaric oxygen therapy for late radiation tissue injury. *Cochr Database Systemat Rev* 2016;4:CD005005.
- Oscarsson N, Muller B, Rosen A, Lodding P, Molne J, Giglio D, et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2–3 trial. *Lancet Oncol* 2019.
- Kirby JP. Hyperbaric oxygen therapy and radiation-induced injuries. *Mo Med* 2019;116:198–200.
- Kirby JP. Hyperbaric oxygen indications: diabetic foot ulcers and intractable management. *Mo Med* 2019;116:188–91.
- Han CH, Zhang PX, Xu WG, Li RP, Xu JJ, Liu WW. Polarization of macrophages in the blood after decompression in mice. *Med Gas Res* 2017;7:236–40.
- Geng M, Zhou L, Liu X, Li P. Hyperbaric oxygen treatment reduced the lung injury of type II decompression sickness. *Int J Clin Exp Pathol* 2015;8:1797–803.
- Buras JA, Holt D, Orlow D, Belikoff B, Pavlides S, Reenstra WR. Hyperbaric oxygen protects from sepsis mortality via an interleukin-10-dependent mechanism. *Crit Care Med* 2006;34:2624–9.
- Oyaizu T, Enomoto M, Yamamoto N, Tsuji K, Horie M, Muneta T, et al. Hyperbaric oxygen reduces inflammation, oxygenates injured muscle, and regenerates skeletal muscle via macrophage and satellite cell activation. *Sci Rep* 2018;8:1288.
- Benson RM, Minter LM, Osborne BA, Granowitz EV. Hyperbaric oxygen inhibits stimulus-induced proinflammatory cytokine synthesis by human blood-derived monocyte-macrophages. *Clin Exp Immunol* 2003;134:57–62.
- Dong H, Li J, Lv Y, Zhou Y, Wang G, Hu S, et al. Comparative analysis of the alveolar macrophage proteome in ALI/ARDS patients between the exudative phase and recovery phase. *BMC Immunol* 2013;14:25.
- De Maio A, Hightower LE. COVID-19, acute respiratory distress syndrome (ARDS) and hyperbaric oxygen therapy (HBOT): what is the link? *Cell Stress Chaperones* 2020(May 18):1–4. <https://doi.org/10.1007/s12192-020-01121-0>.
- Tezgin D, Giardina C, Perdrizet GA, Hightower LE. The effect of hyperbaric oxygen on mitochondrial and glycolytic energy metabolism: the caloristasis concept. *Cell Stress Chaperones* 2020;25(4):667–77. <https://doi.org/10.1007/s12192-020-01100-5>.
- Edremittioğlu M, Kilic D, Oter S, Kisa U, Korkmaz A, Coskun O, et al. The effect of hyperbaric oxygen treatment on the renal functions in septic rats: relation to oxidative damage. *Surg Today* 2005;35:653–61.
- Buras JA, Reenstra WR. Endothelial-neutrophil interactions during ischemia and reperfusion injury: basic mechanisms of hyperbaric oxygen. *Neurol Res* 2007;29:127–31.
- Yu SY, Chiu JH, Yang SD, Yu HY, Hsieh CC, Chen PJ, et al. Preconditioned hyperbaric oxygenation protects the liver against ischemia-reperfusion injury in rats. *J Surg Res* 2005;128:28–36.
- Fuller AM, Giardina C, Hightower LE, Perdrizet GA, Tierney CA. Hyperbaric oxygen preconditioning protects skin from UV-A damage. *Cell Stress Chaperones* 2013;18:97–107.
- Harrison LE, Giardina C, Hightower LE, Anderson C, Perdrizet GA. Might hyperbaric oxygen therapy (HBOT) reduce renal injury in diabetic people with diabetes mellitus? From preclinical models to human metabolomics. *Cell Stress Chaperones* 2018;23:1143–52.
- Halbach JL, Prieto JM, Wang AW, Hawisher D, Cauvi DM, Reyes T, et al. Early hyperbaric oxygen therapy improves survival in a model of severe sepsis. *Am J Physiol Regul Integr Comp Physiol* 2019;317:R160–8.
- Thom SR, Lauerer MW, Hart GB. Intermittent hyperbaric oxygen therapy for reduction of mortality in experimental polymicrobial sepsis. *J Infect Dis* 1986;154:504–10.
- Weislow OS, Pakman LM. Inhibition of *Pseudomonas aeruginosa* by hyperbaric oxygen: interaction with mouse peritoneal exudate cells. *Infect Immun* 1974;10:546–52.
- Lin HC, Wan FJ, Wu CC, Tung CS, Wu TH. Hyperbaric oxygen protects against lipopolysaccharide-stimulated oxidative stress and mortality in rats. *Eur J Pharmacol* 2005;508:249–54.
- Pedoto A, Nandi J, Yang ZJ, Wang J, Bosco G, Oler A, et al. Beneficial effect of hyperbaric oxygen pretreatment on lipopolysaccharide-induced shock in rats. *Clin Exp Pharmacol Physiol* 2003;30:482–8.
- Thom SR. Oxidative stress is fundamental to hyperbaric oxygen therapy. *J Appl Physiol* 1985;2009(106):988–95.
- Guerard S, Holmdahl R, Wing K. Reactive oxygen species regulate innate but not adaptive inflammation in ZAP70-mutated SKG arthritic mice. *Am J Pathol* 2016.
- Novak S, Drenjancevic I, Vukovic R, Kellermayer Z, Cosic A, Tolusic Levak M, et al. Anti-inflammatory effects of hyperbaric oxygenation during DSS-induced colitis in BALB/c mice include changes in gene expression of HIF-1 α , proinflammatory cytokines, and antioxidative enzymes. *Mediators Inflamm* 2016;2016:7141430.
- Salhanick SD, Belikoff B, Orlow D, Holt D, Reenstra W, Buras JA. Hyperbaric oxygen reduces acetaminophen toxicity and increases HIF-1 α expression. *Acad Emerg Med* 2006;13:707–14.
- Anguiano-Hernandez YM, Contreras-Mendez L, de Los Angeles Hernandez-Cueto M, Muand Oz-Medina JE, Santillan-Verde MA, Barbosa-Cabrera RE, Delgado-Quintana CA, Trejo-Rosas S, Santacruz-Tinoco CE, Gonzalez-Ibarra J, Gonzalez-Bonilla CR. Modification of HIF-1 α , NF- κ B, IGFBP-3, VEGF and adiponectin in diabetic foot ulcers treated with hyperbaric oxygen. *Undersea Hyperb Med* 2019; 46: 35–44.
- Godman CA, Chheda KP, Hightower LE, Perdrizet G, Shin DG, Giardina C. Hyperbaric oxygen induces a cytoprotective and angiogenic response in human microvascular endothelial cells. *Cell Stress Chaperones* 2010;15:431–42.
- Lisagors IL, Sondore A, Pupelis G, Oshs P, launalksne I, Pavars M, et al. Impact of hyperbaric oxygen therapy on the clinical course of acute pancreatitis and systemic inflammation response syndrome. *Anesteziol Reanimatol* 2008;34–8.
- Dulai PS, Buckley Jr. JC, Raffals LE, Swoger JM, Claus PL, O'Toole K, et al. Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial. *Am J Gastroenterol* 2018.
- Kallet RH, Branson RD. Should oxygen therapy be tightly regulated to minimize hyperoxia in critically ill patients? *Respiratory Care* 2016;61:801–17.
- Heyboer 3rd M, Sharma D, Santiago W, McCulloch N. Hyperbaric oxygen therapy: side effects defined and quantified. *Adv Wound Care (New Rochelle)* 2017;6:210–24.
- Wingelaar TT, van Ooij PAM, van Hulst RA. Oxygen toxicity and special operations forces diving: hidden and dangerous. *Front Psychol* 2017;8:1263.
- Chavko M, Mahon RT, McCarron RM. Mechanisms of protection against pulmonary hyperbaric O₂ toxicity by intermittent air breaks. *Eur J Appl Physiol* 2008;102:525–32.
- Zhang L, Zhang Y, Wang Z, Chen Y, Li R. Intermittent hyperbaric oxygen exposure mobilizing peroxiredoxin 6 to prevent oxygen toxicity. *J Physiol Sci* 2019;69:779–90.
- Moon RD, Weaver LK. Hyperbaric oxygen as a treatment for COVID-19 infection? *Undersea Hyperb Med* 2020;47:177–9.
- Guo D, Pan S, Wang M, Guo Y. Hyperbaric oxygen therapy may be effective to improve hypoxemia in patients with severe COVID-2019 pneumonia: two case reports. *Undersea Hyperb Med* 2020;47:181–7.
- Thibodeaux K, Speyrer M, Raza A, Yaakov R, Serena TE. Hyperbaric oxygen therapy in preventing mechanical ventilation in COVID-19 patients: a retrospective case series. *J Wound Care* 2020;29:S4–8.
- Bessereau J, Aboab J, Hullin T, Huon-Bessereau A, Bourgeois JL, Brun PM, et al. Safety of hyperbaric oxygen therapy in mechanically ventilated patients. *Int Marit Health* 2017;68:46–51.